Trending NewsTrending NewsNASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $4.08 -0.07 (-1.69%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$4.05 -0.03 (-0.71%) As of 09/25/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ARS Pharmaceuticals Stock (NASDAQ:SPRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.02▼$4.1850-Day Range$4.08▼$6.4452-Week Range$4.02▼$13.15Volume1.03 million shsAverage Volume1.42 million shsMarket Capitalization$405.74 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingModerate Buy Company Overview ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy, an epinephrine nasal spray designed to provide emergency treatment for allergic reactions, including anaphylaxis, without requiring an injection. The U.S. Food and Drug Administration approved neffy in 2024 for adults and children who weigh at least 30 kilograms. The product is intended for use when epinephrine is needed and is designed to address barriers associated with injectable epinephrine, such as needle fear, difficulty with administration, and hesitation to use an auto-injector. ARS Pharmaceuticals was founded in 2015 and is headquartered in San Mateo, California. The company’s operations are primarily focused on advancing and commercializing its epinephrine nasal spray platform and expanding access to emergency allergy treatment in the United States and other markets where the product receives regulatory authorization. Richard Low serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More ARS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreSPRY MarketRank™: ARS Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 676th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingARS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialARS Pharmaceuticals has a consensus price target of $25.00, representing about 512.7% upside from its current price of $4.08.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($1.90) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ARS Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.05% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 15.51, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently decreased by 0.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.17 News SentimentARS Pharmaceuticals has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 28 news articles for ARS Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for SPRY on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders33.80% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRY Stock News HeadlinesSPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026September 26 at 8:23 AM | globenewswire.comSPRY DEADLINE: ROSEN, TRUSTED INVESTOR RIGHTS COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYSeptember 25 at 10:17 PM | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 27 at 1:00 AM | Base Camp Trading (Ad)Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.September 25 at 6:33 PM | globenewswire.comKaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Who Suffered Losses to a Securities Class Action – Deadline is October 5, 2026September 25 at 9:45 AM | globenewswire.comKaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026September 24 at 11:52 PM | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRYSeptember 24 at 4:15 PM | prnewswire.comBragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff RoleSeptember 24 at 4:00 PM | globenewswire.comSee More Headlines SPRY Stock Analysis - Frequently Asked Questions How have SPRY shares performed this year? ARS Pharmaceuticals' stock was trading at $11.65 at the beginning of the year. Since then, SPRY shares have decreased by 65.0% and is now trading at $4.08. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced its earnings results on Thursday, August, 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.15. The business had revenue of $33.66 million for the quarter, compared to analysts' expectations of $31.32 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 256.67% and a negative net margin of 184.24%. Read the conference call transcript. When did ARS Pharmaceuticals IPO? ARS Pharmaceuticals (SPRY) raised $207 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 11,500,000 shares at a price of $17.00-$19.00 per share. Who are ARS Pharmaceuticals' major shareholders? Top institutional investors of ARS Pharmaceuticals include BlackRock Inc. (5.35%), Tejara Capital Ltd (0.61%), ADAR1 Capital Management LLC (0.61%) and Bank of America Corp DE (0.47%). Insiders that own company stock include Ra Capital Management, LP, Sarina Tanimoto, Richard E Lowenthal, Laura Shawver, Alexander A Fitzpatrick, Eric Karas, Brian Dorsey, Kathleen D Scott, Peter A Thompson, Justin Chakma and Brent L Saunders. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/13/2026Today9/27/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SPRY's financial health is in the Red zone, according to TradeSmith. SPRY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SPRY CIK1671858 Webars-pharma.com Phone(858) 771-9307FaxN/AEmployees200Year Founded2015Price Target and Rating Average Price Target for ARS Pharmaceuticals$25.00 High Price Target$30.00 Low Price Target$15.00 Potential Upside/Downside+512.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$171.30 million Net Margins-184.24% Pretax Margin-184.31% Return on Equity-256.67% Return on Assets-69.63% Debt Debt-to-Equity Ratio13.72 Current Ratio3.48 Quick Ratio3.28 Sales & Book Value Annual Sales$116.93 million Price / Sales3.47 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book3.52Miscellaneous Outstanding Shares99,447,000Free Float65,834,000Market Cap$405.74 million OptionableOptionable Beta1.05 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SPRY) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
